Physician profile
Peter G Levinson
NPI 1881612851
$9,760.45
in general payments reported to CMS, 2019-2025
47 companies · $687 in 2025
The $687 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,101 · 2020: $1,291 · 2021: $38.09 · 2022: $1,074 · 2023: $2,148 · 2024: $1,421 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,067 · Education: $129 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,067.35 |
| Education | $129.26 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,104.28 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $1,010.68 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $844.19 | 2022-2025 | |
| Glaxosmithkline, LLC. | $674.77 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $640.87 | 2019-2024 | Airsupra, Breztri, Flumist Quadrivalent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $594.97 | 2019-2024 | Jardiance, Ofev |
| Amarin Pharma, INC. | $584.55 | 2019-2023 | |
| Amgen INC. | $503.79 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $375.99 | 2019-2024 | |
| Exact Sciences Corporation | $330.62 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $296.57 | 2019-2020 | |
| Abbott Laboratories | $283.88 | 2019-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $266.92 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $257.12 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $222.55 | 2019-2025 | Jardiance, Trulicity, Mounjaro |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Levinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.